Genvor Incorporated

What they do

Genvor operates through its wholly owned Delaware subsidiary, Genvor Inc., developing an AI-enabled peptide platform built on the proprietary BioCypher algorithm and a peptide library. Its lead antimicrobial peptide candidates, AGM182, GV185 and GV187, have been tested in vitro and in transgenic maize greenhouse studies. The company is pursuing two agricultural commercialization pathways: seed traits, where peptides are expressed internally by crops, and foliar biological crop protection products applied externally. It also intends to license peptide candidates to third parties in agriculture and in human health and wellness under a business-to-business model.

Revenue drivers

• Foliar biological crop protection — Peptide-based fungicides, insecticides and emerging biostimulants intended to be sold as applied crop protection products. This is a stated intended future revenue line; no revenue has been reported to date.
• Seed traits — Insect resistance traits, with fungal resistance and nutritional enhancement/quality described as emerging, in which peptides are expressed within the crop itself. Stated as an intended pathway; no revenue to date.
• Peptide licensing (agriculture and human health and wellness) — Intended B2B model in which Genvor designs, identifies, optimizes and licenses peptide candidates to third parties for consumer health, wellness, cosmetic, topical, nutraceutical and functional support uses. No licensing revenue has been reported.

Recent performance

Genvor has reported no revenue in every period for which XBRL data is provided, including annual periods from 2019 through 2021 and quarterly periods through 2022-06-30. Annual net loss widened from $1.7 million in 2023 to $2.9 million in 2024 and $5.6 million in 2025, with diluted EPS of -$0.07, -$0.15 and -$0.22 respectively. Operating cash outflow was $871,734 in 2023, $975,641 in 2024 and $555,717 in 2025. At 2026-06-30 the company reported total assets of $312,243, total liabilities of $3.0 million, shareholder equity of -$2.7 million and cash and equivalents of $196,522. Long-term debt of $20,000 was reported as of 2025-09-30.

Strategy

Management states it intends to focus over the next four years on researching and developing portfolio solutions across foliar segments (fungicides, insecticides, emerging biostimulants) and traits segments (insect resistance, emerging fungal resistance, emerging nutritional enhancement and quality). The company describes its agricultural commercialization strategy as two complementary pathways: seed traits expressed internally by crops and foliar biological products applied externally. It also intends to use BioCypher and its peptide library to design, identify, optimize and license candidates to third parties, including in human health and wellness. Management states the company is not currently positioned as a vertically integrated direct-to-consumer wellness product company, and that its market entry approach emphasizes capital efficiency through strategic partners.

Risks

• No revenue and recurring losses — Genvor has reported zero revenue across all periods shown and a net loss of $5.6 million in 2025, with no commercial product yet generating sales.
• Negative shareholder equity and limited cash — At 2026-06-30 shareholder equity was -$2.7 million against total liabilities of $3.0 million and cash of $196,522, indicating dependence on further financing.
• Early-stage product pipeline — Lead candidates AGM182, GV185 and GV187 have advanced only to in vitro testing and transgenic maize greenhouse studies, with no field-scale or commercial validation described.
• Regulatory and market adoption — The company states its peptide solutions are designed to meet regulatory requirements for residue-free agricultural products while matching conventional pesticide efficacy, but no approvals or commercial partnerships are disclosed in the excerpts.

Outlook

Management states that over the next four years it intends to focus on researching and developing portfolio solutions in foliar fungicides, insecticides and emerging biostimulants, and in traits for insect resistance, emerging fungal resistance and emerging nutritional enhancement and quality. It also intends to pursue licensing of peptide candidates to third parties in agriculture and human health and wellness. The filings describe continued development of the BioCypher platform and the peptide library, but no timeline, revenue guidance or committed partner arrangements are provided in the excerpts.